{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:38:21Z","timestamp":1792708701626,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,6,27]],"date-time":"2012-06-27T00:00:00Z","timestamp":1340755200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/s10549-012-2137-y","type":"journal-article","created":{"date-parts":[[2012,6,27]],"date-time":"2012-06-27T07:50:10Z","timestamp":1340783410000},"page":"189-200","source":"Crossref","is-referenced-by-count":47,"title":["111In-Bn-DTPA-nimotuzumab with\/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer"],"prefix":"10.1007","volume":"135","author":[{"given":"Aisha","family":"Fasih","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humphrey","family":"Fonge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongli","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey V.","family":"Leyton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilia","family":"Tikhomirov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan J.","family":"Done","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond M.","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,6,27]]},"reference":[{"key":"2137_CR1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3816\/CBC.2004.n.011","volume":"5","author":"MA Owens","year":"2004","unstructured":"Owens MA, Horten BC, Da Silva MM (2004) HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 5:63\u201369","journal-title":"Clin Breast Cancer"},{"key":"2137_CR2","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","volume":"25","author":"AC Wolff","year":"2007","unstructured":"Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118\u2013145","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"2137_CR3","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S0959-8049(00)00404-4","volume":"37","author":"J Baselga","year":"2001","unstructured":"Baselga J (2001) Clinical trials of Herceptin (trastuzumab). Eur J Cancer 37(Suppl 1):18\u201324","journal-title":"Eur J Cancer"},{"key":"2137_CR4","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.yexcr.2010.01.009","volume":"316","author":"TJ Kruser","year":"2010","unstructured":"Kruser TJ, Wheeler DL (2010) Mechanisms of resistance to HER family targeting antibodies. Exp Cell Res 316:1083\u20131100","journal-title":"Exp Cell Res"},{"key":"2137_CR5","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1158\/1078-0432.CCR-05-1109","volume":"12","author":"JM Manoir du","year":"2006","unstructured":"du Manoir JM, Francia G, Man S et al (2006) Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin Cancer Res 12:904\u2013916","journal-title":"Clin Cancer Res"},{"key":"2137_CR6","first-page":"827","volume":"47","author":"P Chen","year":"2006","unstructured":"Chen P, Wang J, Hope K et al (2006) Nuclear localizing sequences (NLS) promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells. J Nucl Med 47:827\u2013836","journal-title":"J Nucl Med"},{"key":"2137_CR7","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.2967\/jnumed.106.037937","volume":"48","author":"DL Costantini","year":"2007","unstructured":"Costantini DL, Chan C, Cai Z, Vallis KA, Reilly RM (2007) 111In-labeled trastuzumab (Herceptin) modified with nuclear localizing sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2\/neu-amplified breast cancer. J Nucl Med 48:1357\u20131368","journal-title":"J Nucl Med"},{"key":"2137_CR8","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.2967\/jnumed.111.087668","volume":"52","author":"JV Leyton","year":"2011","unstructured":"Leyton JV, Hu M, Gao C et al (2011) Auger electron radioimmunotherapeutic agent specific for the CD123+\/CD131\u2212 phenotype of the leukemia stem cell population. J Nucl Med 52:1465\u20131473","journal-title":"J Nucl Med"},{"key":"2137_CR9","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.2967\/jnumed.109.072389","volume":"51","author":"DL Costantini","year":"2010","unstructured":"Costantini DL, McLarty K, Lee H, Done SJ, Vallis KA, Reilly RM (2010) Antitumor effects and normal-tissue toxicity of 111In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer xenografts. J Nucl Med 51:1084\u20131091","journal-title":"J Nucl Med"},{"key":"2137_CR10","first-page":"429","volume":"41","author":"RM Reilly","year":"2000","unstructured":"Reilly RM, Kiarash R, Cameron R et al (2000) 111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR. J Nucl Med 41:429\u2013438","journal-title":"J Nucl Med"},{"key":"2137_CR11","first-page":"1469","volume":"44","author":"P Chen","year":"2003","unstructured":"Chen P, Cameron R, Wang J, Vallis KA, Reilly RM (2003) Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts. J Nucl Med 44:1469\u20131478","journal-title":"J Nucl Med"},{"key":"2137_CR12","first-page":"987","volume-title":"Handbook of biopharmaceutical technology","author":"RM Reilly","year":"2007","unstructured":"Reilly RM (2007) The radiopharmaceutical science of monoclonal antibodies and peptides for imaging and targeted in situ radiotherapy of malignancies. In: Gad SC (ed) Handbook of biopharmaceutical technology. Wiley, Toronto, pp 987\u20131053"},{"key":"2137_CR13","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00259-005-1908-7","volume":"33","author":"M Hu","year":"2006","unstructured":"Hu M, Chen P, Wang J, Chan C, Scollard DA, Reilly RM (2006) Site-specific conjugation of HIV-1 tat peptides to IgG: a potential route to construct radioimmunoconjugates for targeting intracellular and nuclear epitopes in cancer. Eur J Nucl Med Mol Imaging 33:301\u2013310","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2137_CR14","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2967\/jnumed.108.051805","volume":"49","author":"Z Cai","year":"2008","unstructured":"Cai Z, Chen Z, Bailey KE, Scollard DA, Reilly RM, Vallis KA (2008) Relationship between induction of phosphorylated H2AX and survival in breast cancer cells exposed to 111In-DTPA-hEGF. J Nucl Med 49:1353\u20131361","journal-title":"J Nucl Med"},{"key":"2137_CR15","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1080\/09553000902748757","volume":"85","author":"Z Cai","year":"2009","unstructured":"Cai Z, Vallis KA, Reilly RM (2009) Computational analysis of the number, area and density of gamma-H2AX foci in breast cancer cells exposed to 111In-DTPA-hEGF or gamma-rays using Image-J software. Int J Radiat Biol 85:262\u2013271","journal-title":"Int J Radiat Biol"},{"key":"2137_CR16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/cbr.2007.0430","volume":"23","author":"DL Costantini","year":"2008","unstructured":"Costantini DL, Hu M, Reilly RM (2008) Peptide motifs for insertion of radiolabeled biomolecules into cells and routing to the nucleus for cancer imaging or radiotherapeutic applications. Cancer Biother Radiopharm 23:3\u201324","journal-title":"Cancer Biother Radiopharm"},{"key":"2137_CR17","doi-asserted-by":"crossref","first-page":"10432","DOI":"10.1074\/jbc.M610014200","volume":"282","author":"SC Hsu","year":"2007","unstructured":"Hsu SC, Hung MC (2007) Characterization of a novel tripartite nuclear localization sequence in the EGFR family. J Biol Chem 282:10432\u201310440","journal-title":"J Biol Chem"},{"key":"2137_CR18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10549-005-9011-0","volume":"95","author":"HW Lo","year":"2006","unstructured":"Lo HW, Hsu SC, Hung MC (2006) EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Res Treat 95:211\u2013218","journal-title":"Breast Cancer Res Treat"},{"key":"2137_CR19","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1002\/jcb.20876","volume":"98","author":"HW Lo","year":"2006","unstructured":"Lo HW, Ali-Seyed M, Wu Y, Bartholomeusz G, Hsu SC, Hung MC (2006) Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin beta1 and CRM1. J Cell Biochem 98:1570\u20131583","journal-title":"J Cell Biochem"},{"key":"2137_CR20","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.nucmedbio.2007.06.010","volume":"34","author":"M Hu","year":"2007","unstructured":"Hu M, Scollard D, Chan C, Chen P, Vallis K, Reilly RM (2007) Effect of the EGFR density of breast cancer cells on nuclear importation, in vitro cytotoxicity, and tumor and normal-tissue uptake of [111In]DTPA-hEGF. Nucl Med Biol 34:887\u2013896","journal-title":"Nucl Med Biol"},{"key":"2137_CR21","doi-asserted-by":"crossref","first-page":"6179","DOI":"10.1158\/0008-5472.CAN-09-0049","volume":"69","author":"HJ Liao","year":"2009","unstructured":"Liao HJ, Carpenter G (2009) Cetuximab\/C225-induced intracellular trafficking of epidermal growth factor receptor. Cancer Res 69:6179\u20136183","journal-title":"Cancer Res"},{"key":"2137_CR22","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00259-008-0923-x","volume":"36","author":"K McLarty","year":"2009","unstructured":"McLarty K, Cornelissen B, Scollard DA, Done SJ, Chun K, Reilly RM (2009) Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts. Eur J Nucl Med Mol Imaging 36:81\u201393","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2137_CR23","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.nucmedbio.2008.05.010","volume":"35","author":"B Cornelissen","year":"2008","unstructured":"Cornelissen B, McLarty K, Kersemans V, Reilly RM (2008) The level of insulin growth factor-1 receptor expression is directly correlated with the tumor uptake of 111In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin). Nucl Med Biol 35:645\u2013653","journal-title":"Nucl Med Biol"},{"key":"2137_CR24","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.2967\/jnumed.108.051771","volume":"49","author":"DL Costantini","year":"2008","unstructured":"Costantini DL, Bateman K, McLarty K, Vallis KA, Reilly RM (2008) Trastuzumab-resistant breast cancer cells remain sensitive to the Auger electron-emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate. J Nucl Med 49:1498\u20131505","journal-title":"J Nucl Med"},{"key":"2137_CR25","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1007\/s002590000293","volume":"27","author":"H Kobayashi","year":"2000","unstructured":"Kobayashi H, Sato N, Saga T et al (2000) Monoclonal antibody-dendrimer conjugates enable radiolabeling of antibody with markedly high specific activity with minimal loss of immunoreactivity. Eur J Nucl Med 27:1334\u20131339","journal-title":"Eur J Nucl Med"},{"key":"2137_CR26","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1021\/mp100223d","volume":"7","author":"D Sarko","year":"2010","unstructured":"Sarko D, Beijer B, Boy RG et al (2010) The pharmacokinetics of cell-penetrating peptides. Mol Pharm 7:2224\u20132231","journal-title":"Mol Pharm"},{"key":"2137_CR27","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1021\/bc0155061","volume":"12","author":"HJ Lee","year":"2001","unstructured":"Lee HJ, Pardridge WM (2001) Pharmacokinetics and delivery of tat and tat-protein conjugates to tissues in vivo. Bioconjug Chem 12:995\u2013999","journal-title":"Bioconjug Chem"},{"key":"2137_CR28","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1021\/bc050258k","volume":"17","author":"S Kameyama","year":"2006","unstructured":"Kameyama S, Horie M, Kikuchi T et al (2006) Effects of cell-penetrating peptide binding on the distribution of 125I-labeled Fab fragment in rats. Bioconjug Chem 17:597\u2013602","journal-title":"Bioconjug Chem"},{"key":"2137_CR29","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1016\/j.yexcr.2008.07.013","volume":"314","author":"M Perez-Torres","year":"2008","unstructured":"Perez-Torres M, Valle BL, Maihle NJ et al (2008) Shedding of epidermal growth factor receptor is a regulated process that occures with overexpression in malignant cells. Exp Cell Res 314:2907\u20132918","journal-title":"Exp Cell Res"},{"key":"2137_CR30","doi-asserted-by":"crossref","first-page":"657","DOI":"10.4161\/cbt.5.6.2708","volume":"5","author":"PC Liu","year":"2006","unstructured":"Liu PC, Liu X, Covington M et al (2006) Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells. Cancer Biol Ther 5:657\u2013664","journal-title":"Cancer Biol Ther"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-012-2137-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-012-2137-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-012-2137-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T16:34:03Z","timestamp":1559234043000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-012-2137-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,27]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["2137"],"URL":"https:\/\/doi.org\/10.1007\/s10549-012-2137-y","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,27]]}}}